Skip to main content
. 2020 Jul 27;12(8):2076. doi: 10.3390/cancers12082076
Ab antibody
CI Confidence interval
ER Estrogen Receptor
Her2 Human Epidermal Growth Factor Receptor-2
HR hormone receptor
HdR hazard ratio
IF immunofluorescence
IHC Immunohistochemistry
ISH in situ hybridization
PR Progesterone Receptor
ROI Region of interest
SBR Scarff–Bloom–Richardson
TNBC Triple-Negative Breast Cancer
TTR Time To Relapse